Search company, investor...
Omeros company logo

Omeros

omeros.com

Founded Year

1994

Stage

PIPE | IPO

Total Raised

$78.57M

Market Cap

0.18B

Stock Price

2.58

About Omeros

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies, and disorders of the central nervous system. The company's products are derived from its PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, surgical, and medical procedures. The company was founded in 1994 and is based in Seattle, Washington.

Headquarters Location

201 Elliott Avenue West

Seattle, Washington, 98119,

United States

206-676-5000

Missing: Omeros's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Omeros's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Omeros Patents

Omeros has filed 164 patents.

The 3 most popular patent topics include:

  • Complement system
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/11/2019

12/13/2022

Complement system, Immune system, Clusters of differentiation, Immunology, EC 3.4.21

Grant

Application Date

7/11/2019

Grant Date

12/13/2022

Title

Related Topics

Complement system, Immune system, Clusters of differentiation, Immunology, EC 3.4.21

Status

Grant

Latest Omeros News

Opioid Use Disorder Market is geared to grow at a CAGR of 9% by 2032, owing to increasing cases of opioid addiction | insightSLICE

Jan 2, 2023

| insightSLICE According to estimates, the global market for Opioid Use Disorder was worth US$ 2.65 billion in 2021, growing at a CAGR of 9% through 2032. The “Opioid Use Disorder Market” study will give you a briefing on current trends, market data, and sales estimates for the years 2023-2032. This report uses data from the year 2021 as its historical baseline and data from the year 2022 as its observational baseline. Access the sample report:  https://www.insightslice.com/request-sample/844 The study considers the overall major landscape of the market in addition to providing a comprehensive business profile and market forecast for each of the leading participants in the worldwide market for opioid use disorders. For all of the major companies in this market, the report will also include data on local trading activity, revenue growth rates, future research prospects, quality indicators, leadership profiles, and brand impact. The key players of the Global Opioid Use Disorder Market are: The key players in the Global Opioid Use Disorder Market are Indivior PLC, Titan Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC, Alkermes, Inc., Omeros Corporation, BioDelivery Sciences International, Inc., Camurus, and others. Factors enabling increased requirement for opioid use disorder treatment: Nowadays, everyone deals with a wide range of severe and continuous medical problems, such as pain from injuries or illnesses. They frequently cause ongoing suffering, and in these situations, patients are prescribed medications, especially opioids. While they aid in relieving suffering, patients may develop habits as a result. These medicines’ withdrawal symptoms are brought on by abrupt quitting or increased dependence. This increases the likelihood of fatal outcomes, such as fatalities and deaths in users of such drugs. Opioid Use Disorder (OUD) is a persistent condition linked to the repeated, delayed, and urgent use of opioids. Patients with OUD fall into two categories: those who are dependent on prescription opioids and those who are hooked on non-prescription opioids. Read more about the report inclusions:  https://www.insightslice.com/opioid-use-disorder-market A combination of inherited and natural factors affects the patient, yet a single cause cannot be accurately reflected by OUD. Due to Suboxone’s outstanding clinical profile, it is the medicine that is most frequently recommended in the OUD marketplace. The high acceptance of this medication can be attributed to its strong efficacy in managing addiction, a minimal possibility for abuse, rather mild unpleasant effects, and good model integration. Global Opioid Use Disorder Market Key Segments: Based on drug class Primary propellers of various market segments: The buprenorphine-sublocade market is predicted to grow at the fastest rate because it addresses the treatment’s drawbacks by substituting an injection for daily oral medications, which makes misuse and diversion more difficult while also promoting personal fulfillment. Due to the opioid crisis sweeping through the United States and Canada as well as the local government’s development of emergency management plans, North America has the largest market. In January 2018, the American government launched a campaign to raise awareness about opioid addiction. Due to the patient population’s dependence on these facilities for the administration of injectable OUD medications, such as buprenorphine, the clinic drug shops sector is anticipated to hold a larger part of the global market. Proceed to purchase:  https://www.insightslice.com/buy-now/844 Due to the patient population’s dependency on these locations for finishing out their prescriptions, the retail drug shops and stores category is predicted to grow to be the second-largest segment during the upcoming years. Regional growth statistics for Opioid Use Disorder market: The largest income-producing region for Opioid use disorder management in 2019 was the North American continent. This market is anticipated that this pattern would continue throughout the projected period. The opioid epidemic in the United States and Canada is likely the biggest contributor to the largest share of North America’s entire business. Governments are familiarizing themselves with a few incident management tactics. For instance, the American government launched an awareness-raising campaign to combat the opiate epidemic in January 2018. Market report provides valuable insights: The report includes an in-depth assessment of significant companies with a substantial share of the global market, with such a priority on all functioning core businesses, and it would identify the industry’s department specializing just in Global Opioid Use Disorders Segment. Additionally, it will calculate the market shares of well-known firms in the global market for opioid use disorders. The study considers important competitive characteristics including company strategy, sales strategy, key advancement, opportunities and threats, and R&D strategy of all Opioid Use Disorder companies. The parties involved in the market’s supply chain and value chain, as well as their contributions, will be taken into account in the global study of opioid use disorder. The Opioid Use Disorder corporate sector and the company’s product range would be the main emphasis of some sections on ours. The section on recent developments shall recommend investment strategies based on the most recent activities, strategic alliances, licensing and manufacturing partnerships, mergers, hostile acquisitions, the introduction of new products, as well as geographic expansion in the global market for opioid use disorder. Related reports: Global Dementia Care Products Market: https://www.insightslice.com/dementia-care-products-market insightSLICE  is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at  info@insightslice.com . Contact us:

Omeros Frequently Asked Questions (FAQ)

  • When was Omeros founded?

    Omeros was founded in 1994.

  • Where is Omeros's headquarters?

    Omeros's headquarters is located at 201 Elliott Avenue West, Seattle.

  • What is Omeros's latest funding round?

    Omeros's latest funding round is PIPE.

  • How much did Omeros raise?

    Omeros raised a total of $78.57M.

  • Who are the investors of Omeros?

    Investors of Omeros include Cercano Management, WRF Capital, Stanley Medical Research Institute, ARCH Venture Partners, Novartis Venture Funds and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.